戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 E(2) in 100 mM NaCl at all concentrations of enzyme tested.
2 meaningful or sustained improvement in liver enzyme testing.
3 -fold selectivity vs. a range of kinases and enzymes tested.
4 yed sub-100 nM activity against all HIV-1 RT enzymes tested.
5 nded more efficiently than 8-oxo-dGTP by all enzymes tested.
6 teins for all of the tryptophan biosynthetic enzymes tested.
7 tive blood cultures and all 14 carbapenemase enzymes tested.
8 lities in the activity of four additional KP enzymes tested.
9    Reactivation rates are equivalent for all enzymes tested (1 x 10(-)(4) s(-)(1)), indicating hydrol
10 ings may help in the interpretation of liver-enzyme tests and provide candidate genes for liver disea
11                                 Plasma liver-enzyme tests are widely used in the clinic for the diagn
12 was inactive against two other DNA-modifying enzymes tested as a counterscreen.
13            The rapid protocol included serum enzyme testing at 0, 3, 6 and 9h, serial electrocardiogr
14                         DM-INDO bound to all enzymes tested, but only inhibited wt mCOX-2 and the V34
15  less than 5% received all recommended liver enzyme tests by the third month of continuous use.
16 values were considered, the results of liver enzyme testing could reduce the probability of an IDU ha
17               Among the different commercial enzymes tested for extraction, Celluclast 10% (36 degree
18 A polymerase was found to be the best of the enzymes tested for this purpose.
19  consists of 4 carbohydrate and 14 preformed enzyme tests, for the identification of 98 clinical isol
20 of the fraction of active molecules for each enzyme tested from both the Fpg/Nei family and HhH-GPD N
21                    To date, all known fungal enzymes tested have great difficulty degrading highly cr
22 owed moderate inhibitory activity toward the enzymes tested (IC50 10-100 microM), the more complex fl
23 s more slippage in vitro than the retroviral enzymes tested including that from HIV.
24 atio of M1-1 among the human GSH transferase enzymes tested is consistent with other work in which GS
25                       For each of two target enzymes tested, lipoamide dehydrogenase and mycobacteria
26                                    Among the enzymes tested, Nmnat1 had the strongest protective effe
27                  Of 57 human cytochrome P450 enzymes tested, only CYP51A1 is capable of circumventing
28          No human microsomal cytochrome P450 enzyme tested, other than CYP3A5, supported these reacti
29 cluded analysis of 24 700 veterans with G6PD enzyme testing prior to January 1, 2020, obtained throug
30 e (WT) C57BL/6 mice, as evaluated by a liver enzyme test, quantitative histology, mononuclear cell (M
31 one orientation, react more rapidly with the enzymes tested than one symmetrical parent but not both.
32 l mode of molecular recognition in which the enzyme tests the suitability of aromatic substrates befo
33  from Toxoplasma gondii (tg) were the target enzymes tested; these organisms are responsible for fata
34                                     For each enzyme tested, we could determine the kinetic constant f
35 N2 disease confirmed by genetic analysis and enzyme testing were eligible for inclusion.
36     Anemia, leukocytosis, and abnormal liver enzyme tests were laboratory findings associated with le
37                               Several of the enzymes tested were capable of inhibiting virus binding
38                                          The enzymes tested were Escherichia coli topo IV and yeast t
39                                        Other enzymes tested were inactivated only with severalfold hi
40        By contrast, GH3.6 and the other five enzymes tested were inactive on halogenated auxins, and
41 mited influence on the Ki values for all the enzymes tested, with the values for p. pepsin remaining
42                              Among the three enzymes tested (yeast Sir2, human SIRT1, and human SIRT2